Northrop Grumman
NYSE: NOC
$544.93 ▼ -4.11  (-0.75%)
At close: Jul 8, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap73.88 Bn
P/E16.14
P/S1.74
Div. Yield0.02
ROIC (Qtr)0.00
Total Debt (Qtr)14.41 Bn
Revenue Growth (1y) (Qtr)4.36
Add ratio to table…

About

Northrop Grumman Corporation is a leading global aerospace and defense technology company. It designs develops produces integrates sustains and modernizes a broad portfolio of systems for air space sea and cyber domains. The company generates revenue primarily through long term contracts with the United States government and international customers. Its sales come from military aircraft missile defense space systems and related sustainment and integration services. The…

Read more ↓
Sector: Industrials Industry: Aerospace & Defense CIK: 0001133421

Investment Thesis

▲ Bull case
  • Northrop Grumman is positioned to capitalize on the accelerating global defense spending environment, with the company's backlog of $96 billion providing over two years of sales coverage and creating a stable foundation for growth. The U.S. defense budget request for fiscal year 2027 represents a 44% increase over current funding levels, with a base budget increase of nearly 30% compared to FY 2026, sustaining support for key programs including B-21, Sentinel, IBCS, and E-2D. This sustained funding environment, coupled with bipartisan support for defense modernization, creates a multi-year tailwind that the market may be underestimating, particularly as the company's international missile defense and counter-UAS opportunities are maturing with export cycle acceleration underway. The company's strategic investments in capacity, including over 20 new facilities and more than 2 million square feet of manufacturing space added in the last two years, are directly aligned with this demand surge and position Northrop Grumman to capture incremental revenue as reconciliation funding flows into contracts later in 2026.
  • The B-21 program represents a significant hidden catalyst for growth, with the Lot 4 LRIP award securing a 25% increase in annual production rate supported by approximately $2.5 billion of company-funded investment phased over multiple years. Management confirmed that the agreement to sell a previously planned test asset accelerated revenue recognition in Q1 without altering the total LRIP delivery count, and that there was no meaningful change in the overall Estimate at Completion (EAC) despite increased production costs being offset by improved profitability in later program phases. This production ramp, combined with the absence of the B-21 loss provision from 2025 that improved Aeronautics Systems margin to 9.3%, sets up the program for enduring growth as it nears 10% of company revenue and is expected to exceed that threshold over the next several years. The market may not be fully appreciating the margin expansion potential from improved production efficiency and scale as the program moves through testing and into full-rate production, particularly given the company's confidence in delivering improved returns over a multiyear period from this investment.
  • Northrop Grumman's missile defense and weapons businesses are each approaching 10% of company sales and are positioned to grow at a pace well above the company average, with the Glide Phase Interceptor (GPI) contract value increasing to $1.3 billion post-quarter and tactical solid rocket motor production capacity already doubled with further expansion completing by 2027. The company highlighted strong international demand in the Middle East and Europe for missile defense and counter-UAS solutions, with Kathy Warden noting that opportunities are moving to the left due to heightened urgency from geopolitical tensions. The Space Systems segment's international backlog is expected to become a major sales contributor within five to ten years, and the company's engagement with international customers on space-related FMS approvals is maturing, with contract awards already announced and a growing pipeline. This diversification into high-growth, high-margin areas like missile defense and space-based interceptors—where Northrop Grumman is a key player in the U.S. Space Force's $3.2 billion space-based interceptor program—provides multiple avenues for upside beyond current guidance that the market may be overlooking.
  • The F/A-XX program presents a material upside opportunity to the 2026 outlook, with Northrop Grumman confident in its ability to deliver the solution and noting that an award selection is expected in Q3 2026. Kathy Warden explicitly stated that winning the F/A-XX contract would provide upside to sales and earnings from current guidance and would be a top priority for the company. Given the Chief of Naval Operations' comment that one competitor lacks the capacity to deliver on time, Northrop Grumman's proven track record with B-21 delivery and its investments in workforce and infrastructure position it favorably in the down-select. The funding for F/A-XX is clear within the defense budget framework, and securing this award would not only add a significant revenue stream but also validate the company's capabilities in next-generation combat aircraft, potentially triggering a re-rating of the stock as investors recognize the program's contribution to long-term growth beyond the current triad modernization focus.
▼ Bear case
  • Northrop Grumman faces significant execution risks in scaling production for major programs like B-21 and Sentinel, despite the optimistic timeline presented by management. The company acknowledged that the B-21 production ramp will be supported by customer funding and approximately $2.5 billion of company-funded investment phased over multiple years, with the majority of capital expenditures expected in the 2027–2029 time frame. This creates a near-term drag on free cash flow, as evidenced by Q1 cash flow use of $1.8 billion, and while management maintains the 2026 free cash flow guidance of $3.1 billion to $3.5 billion, they intentionally did not provide guidance for 2027 or 2028 due to the substantial B-21 CapEx and large awards outstanding. The market may be ignoring the likelihood that the company will struggle to offset the free cash flow impact of this massive investment cycle, particularly if supplier scaling or supply chain bottlenecks persist, as Kathy Warden noted that suppliers need to scale with the company and that work is ongoing to remove bottlenecks in the supply chain.
  • The Space Systems segment continues to face structural headwinds that are being understated in the company's narrative, with Q1 sales and operating income declining due to two specific factors: the $98 million year-over-year headwind from the NGI program contract closeout and a $71 million unfavorable earnings adjustment on GEM 63XL. While management pointed to strong performance elsewhere in the Space portfolio, including growth on SDA programs and restricted space, the segment's international backlog remains the least developed of the four segments, with Kathy Warden acknowledging that it is growing but expecting international to be a key contributor only five to ten years from now. This prolonged timeline for international space revenue contribution, combined with the segment's vulnerability to program closeouts and earnings adjustments, suggests that Space Systems may remain a drag on overall performance for longer than the market anticipates, especially given the competitive intensity in the space domain from players like SpaceX and Lockheed Martin.
  • Despite highlighting strong demand in missile defense and weapons, Northrop Grumman's growth in these areas is contingent on winning new competitive opportunities and converting international pipeline to sales, both of which involve significant uncertainty and timing risks. Kathy Warden explicitly stated that higher sales growth would come from winning numerous new competitive opportunities and accelerating ramp on demand for missile components like solid rocket motors, noting that the company has the capacity but needs to get that on contract and start producing. She also emphasized that converting the international pipeline to sales is necessary for growth beyond mid-single digits, acknowledging that international tends to have a longer cycle than domestic and that steps to accelerate export approval may largely impact the company beyond the current year. This reliance on external factors—competitive win rates, contract timing, and international export approvals—creates vulnerability to delays that the market may be underestimating, particularly if geopolitical shifts or procurement slowdowns affect the anticipated acceleration in demand.
  • The company's restricted/classified business, which Kathy Warden acknowledged had been growing faster than other parts of the business, is expected to grow more in line with the rest of the portfolio going forward due to strong demand in munitions and missile defense. This shift implies a potential deceleration in the growth rate of a historically high-performing segment, which could weigh on overall company growth if not offset by stronger-than-expected performance elsewhere. While Warden framed this as a nice position to be in—seeing growth in both restricted and unrestricted businesses—the market may be ignoring the risk that the slowdown in the restricted business, combined with the longer-cycle nature of international opportunities and the capital-intensive nature of B-21 and Sentinel ramps, could result in a prolonged period of mid-single-digit growth that fails to meet investor expectations for acceleration, especially given the reaffirmed 2026 sales guidance of $43.5 billion to $44 billion representing only 4% year-over-year growth in Q1.

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Aerospace & Defense
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 BA Boeing Co 1,106.33 Bn575.3212.0047.21 Bn
2 RTX RTX Corp 258.51 Bn34.012.8633.20 Bn
3 GD General Dynamics Corp 174.86 Bn40.283.258.01 Bn
4 LMT Lockheed Martin Corp 119.99 Bn25.031.6020.70 Bn
5 HWM Howmet Aerospace Inc. 107.26 Bn61.5412.444.69 Bn
6 TDG TransDigm Group INC 76.18 Bn40.878.0231.28 Bn
7 NOC Northrop Grumman Corp /De/ 73.88 Bn16.141.7414.41 Bn
8 RKLB Rocket Lab Corp 60.59 Bn-331.7789.150.00 Bn